BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
GlobalData on MSN3d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy: Mainz, Germany Friday, November 15, 2024, 14:00 Hrs [IST] BioNTech SE and Biotheus (Biothe ...
Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback